CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
News Sep 19, 2007
CellCyte Genetics Corporation is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart.
Along with its planned human trials for its therapeutics, CellCyte Genetics intends to develop a new stem cell cultivation device or "bioreactor" unit for which CellCyte Genetics owns the worldwide patent and rights.
The Company plans to market the device for applications that will require cells to be grown under regulated oxygen concentrations, e.g. the replication of stem cells and the culture of pancreatic islet cells prior to transplantation into diabetic patients.
Dr. Ron Berninger, Chief Scientific Officer of CellCyte Genetics explains, "CellCyte's patented biological cell maintenance system has the unique ability to incubate cultured cells with a very efficient and regulatable oxygen supply, making it an ideal choice for culturing cells that are otherwise difficult to keep alive or to expand.
Inside the bioreactor, the cells can also form a 3-dimensional network, which is what most cell types do in major organs of the body."
A key element of this bioreactor is the capability to supply oxygen (by bundles of oxygen fibers) to the cells throughout the entire space in which cells are growing.
Stem cells appear to be sensitive to oxygen levels and can be induced to replicate or differentiate in part by controlling the oxygen level.
Using CellCyte's product, scientists, researchers and clinicians should be able to dramatically increase the number of stem cells available for research and potentially for use in stem cell therapies.
Management believes that the bioreactor unit will be the Company's first revenue producing research product and is expected be ready for market in 2008.
CellCyte Genetics acquired the patents and rights to the bioreactor unit and several other key technologies from the developer of the technology in 2006 as part of its original Intellectual property portfolio.
The Company began work on remolding key parts of the bioreactor for manufacturing earlier this year as part of CellCyte's efforts to prepare for human trials and FDA application for the use of its stem cell therapies.
With the manufacturing path and contract suppliers now set, CellCyte has begun gearing up this Device Division to complete development of the bioreactor and several other synergistic technologies.
The Device Division will operate as a separate division of the Company and will carry out R & D, manufacturing, and sales and marketing functions through the facilities of CellCyte Genetics' new facilities in Bothell near Seattle, Washington.
The question of how primitive, undifferentiated cells choose their destiny has tantalized biologists for centuries. New clues about the molecular logic of cell fate show that multipotent cells become biased towards a fate early on and step through a progression of binary decisions as their fate is refined.READ MORE